Valdimara Corrêa Vieira

Valdimara Corrêa Vieira

Auto-generated profile, based on publicly available information

Valdimara Corrêa Vieira

Harvard Med Sch, Dept Immunol, Boston, MA 02115 USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2013 in BioMed Research International
Verified
Journal Article
Open access
PDF file
VVValdimara C. Vieira
Valdimara C. Vieira
MSMarcelo Soares
Marcelo Soares
The APOBEC family of proteins comprises deaminase enzymes that edit DNA and/or RNA sequences. The APOBEC3 subgroup plays an important role on the innate immune system, acting on host defense against exogenous viruses and endogenous retroelements. The role of APOBEC3 proteins in the inhibition of viral infection was firstly described for HIV-1. However, in the past few years many studies have also shown evidence of APOBEC3 action on other viruses associated with human diseases, including HTLV, HCV, HBV, HPV, HSV-1, and EBV. APOBEC3 inhibits these viruses through a series of editing-dependent and independent mechanisms. Many viruses have evolved mechanisms to counteract APOBEC effects, and strategies that enhance APOBEC3 activity constitute a new approach for antiviral drug development. On the other hand, novel evidence that editing by APOBEC3 constitutes a source for viral genetic diversification and evolution has emerged. Furthermore, a possible role in cancer development has been shown for these host enzymes. Therefore, understanding the role of deaminases on the immune response against infectious agents, as well as their role in human disease, has become pivotal. This review summarizes the state-of-the-art knowledge of the impact of APOBEC enzymes on human viruses of distinct families and harboring disparate replication strategies.

1 June 2011 in Memórias do Instituto Oswaldo Cruz
Verified
Journal Article
Open access
PDF file
VVValdimara Corrêa Vieira
Valdimara Corrêa Vieira
MBMaria Fernanda Martínez Barral
Maria Fernanda Martínez Barral
RMRaul Andrés Mendoza-Sassi
Raul Andrés Mendoza-Sassi
JSJussara Maria Silveira
Jussara Maria Silveira
MSMarcelo Alves Soares
Marcelo Alves Soares
AMAna Maria Barral de Martínez
Ana Maria Barral de Martínez
Polymorphisms in genes that encode chemokines or their receptors can modulate susceptibility to human immunodeficiency virus (HIV) infection and disease progression. The objective of this study was to assess the frequency of polymorphisms CCR5-Δ32, CCR2-64I, CCR5-59029A and SDF1-3’A and their role in the course of HIV infection in a southern Brazilian population. Clinical data were obtained from 249 patients for an average period of 6.4 years and genotypes were determined by standard polymerase chain reaction (PCR) and PCR-restriction fragment length polymorphism. Survival analyses were conducted for three outcomes: CD4+ T-cell counts below 200 cells/ μl, acquired immune deficiency syndrome (AIDS) or death. The frequency of the polymorphisms CCR5-Δ32, CCR2- 64I, CCR5-59029A and SDF1-3’A were 0.024, 0.113, 0.487 and 0.207, respectively. CCR5-Δ32 was associated with a reduction in the risk for CD4+ T-cell depletion and with an increased risk for death after AIDS diagnosis. CCR2-64I was associated with a reduction in the risk for developing AIDS. SDF1-3’A was also associated with decreased risk for AIDS, but its effect was only evident when CCR2-64I was present as well. These results highlight the possibility of using these markers as indicators for the prognosis of disease progression and provide evidence for the importance of analysing the effects of gene polymorphisms in a combined fashion

1 August 2021 in Virology
Verified
Journal Article
Closed access
GMGustavo Martínez-Noël
Gustavo Martínez-Noël
VVValdimara Corrêa Vieira
Valdimara Corrêa Vieira
PSPatricia Szajner
Patricia Szajner
ELErin M. Lilienthal
Erin M. Lilienthal
RKRebecca E. Kramer
Rebecca E. Kramer
PHPeter M. Howley
Peter M. Howley